marijuana stocks

Vaporin, Inc. (VAPO)

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013
Total Revenue 837   419   183   (28)
Cost of Revenue 424 238 115
Gross Profit 413   181   67   13  
Operating Expenses
Research Development
Selling General and Administrative 1,792 1,659 821 2,975
Non Recurring
Others 7 3 3
Total Operating Expenses
Operating Income or Loss (1,386) (1,481) (757) (2,963)
Income from Continuing Operations
Total Other Income/Expenses Net 81 135 (130) 581
Earnings Before Interest And Taxes (1,305) (1,346) (887) (2,382)
Interest Expense 53 94 251 102
Income Before Tax (1,358) (1,440) (1,138) (2,484)
Income Tax Expense
Minority Interest
Net Income From Continuing Ops (1,358) (1,440) (1,138) (2,484)
Non-recurring Events
Discontinued Operations (537)
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (1,358) (1,440) (1,138) (3,021)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (1,358) (1,440) (1,138) (3,021)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$EDXC New Director of Commercial Accounts Brendon Riley

Endexx Engages New Director of Commercial Accounts Brendon Riley to Lead Commercial…

Cara Therapeutics, Inc. (CARA) Doses First Patient in Phase 1 Study of Oral CR845

Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845…

Trulieve Cannabis Corp. (TCNNF) Expands Pennsylvania Footprint with Acquisition of Keystone Shops

Trulieve Expands Pennsylvania Footprint with Acquisition of Keystone Shops Trulieve Cannabis Corp.…

$CARA to Webcast Presentation at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

Cara Therapeutics to Webcast Presentation at 22nd Annual BioCentury Future Leaders in…